The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...

Sage Therapeutics SAGE announced that Supernus Pharmaceuticals SUPN has agreed to acquire SAGE through a tender offer of ...

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million, gaining access to the only ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...

Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...

Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential.

Sage Therapeutics Inc. has found itself a buyer that bested the unsolicited acquisition offer a few months ago from fellow ...

Following a turbulent few years, Sage Therapeutics has been acquired by Maryland-based Supernus Pharmaceuticals for up to ...

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

Supernus Pharmaceuticals agreed to buy Sage Therapeutics for $8.50 a share in cash, equal to a total price of about $561 million at closing.